Conversely, CB2 is mainly expressed in immune and peripheral tissues, but its low basal expression in healthy conditions and the dynamic regulation under pathological states (e.g., inflammation, cancer, neurodegeneration) make it difficult to predict efficacy and safety profiles in clinical settings. The gene discussed is CNR2; the disease is cancer.